Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.pharmthera.2020.107579 http://scihub22266oqcxt.onion/10.1016/j.pharmthera.2020.107579 32442437!7236745!32442437     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pharmacol+Ther 2020 ; 213 (ä): 107579 Nephropedia Template TP {{tp|p=32442437|t=2020. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges |pdf=|usr=}}{{32442437}} gab.com Text The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges JO: Pharmacol Ther http://www.kidney.de/pget.php?&tw=1&pmid=32442437 #FOAvip Ubiquitin Proteasome System (UPS) is an adaptable and finely tuned system that sustains proteostasis network under a large variety of physiopathological conditions. Its dysregulation is often associated with the onset and progression of human diseases; hence, UPS modulation has emerged as a promising new avenue for the development of treatments of several relevant pathologies, such as cancer and neurodegeneration. The clinical interest in proteasome inhibition has considerably increased after the FDA approval in 2003 of bortezomib for relapsed/refractory multiple myeloma, which is now used in the front-line setting. Thereafter, two other proteasome inhibitors (carfilzomib and ixazomib), designed to overcome resistance to bortezomib, have been approved for treatment-experienced patients, and a variety of novel inhibitors are currently under preclinical and clinical investigation not only for haematological malignancies but also for solid tumours. However, since UPS collapse leads to toxic misfolded proteins accumulation, proteasome is attracting even more interest as a target for the care of neurodegenerative diseases, which are sustained by UPS impairment. Thus, conceptually, proteasome activation represents an innovative and largely unexplored target for drug development. According to a multidisciplinary approach, spanning from chemistry, biochemistry, molecular biology to pharmacology, this review will summarize the most recent available literature regarding different aspects of proteasome biology, focusing on structure, function and regulation of proteasome in physiological and pathological processes, mostly cancer and neurodegenerative diseases, connecting biochemical features and clinical studies of proteasome targeting drugs. Twit Text FOAVip The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges ????Pharmacol Ther http://www.kidney.de/pget.php?&tw=1&pmid=32442437 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32442437 #FOAvip English Wikipedia <ref>{{Cite pmid|32442437}}</ref> The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges #MMPMID32442437 Tundo GR; Sbardella D; Santoro AM; Coletta A; Oddone F; Grasso G; Milardi D; Lacal PM; Marini S; Purrello R; Graziani G; Coletta M Pharmacol Ther 2020[Sep]; 213 (ä): 107579 PMID32442437show ga Ubiquitin Proteasome System (UPS) is an adaptable and finely tuned system that sustains proteostasis network under a large variety of physiopathological conditions. Its dysregulation is often associated with the onset and progression of human diseases; hence, UPS modulation has emerged as a promising new avenue for the development of treatments of several relevant pathologies, such as cancer and neurodegeneration. The clinical interest in proteasome inhibition has considerably increased after the FDA approval in 2003 of bortezomib for relapsed/refractory multiple myeloma, which is now used in the front-line setting. Thereafter, two other proteasome inhibitors (carfilzomib and ixazomib), designed to overcome resistance to bortezomib, have been approved for treatment-experienced patients, and a variety of novel inhibitors are currently under preclinical and clinical investigation not only for haematological malignancies but also for solid tumours. However, since UPS collapse leads to toxic misfolded proteins accumulation, proteasome is attracting even more interest as a target for the care of neurodegenerative diseases, which are sustained by UPS impairment. Thus, conceptually, proteasome activation represents an innovative and largely unexplored target for drug development. According to a multidisciplinary approach, spanning from chemistry, biochemistry, molecular biology to pharmacology, this review will summarize the most recent available literature regarding different aspects of proteasome biology, focusing on structure, function and regulation of proteasome in physiological and pathological processes, mostly cancer and neurodegenerative diseases, connecting biochemical features and clinical studies of proteasome targeting drugs. |Cyclin-Dependent Kinases/metabolism[MESH] |Drug Resistance/physiology[MESH] |E2F4 Transcription Factor/metabolism[MESH] |Holoenzymes[MESH] |Humans[MESH] |Lipid Droplets/metabolism[MESH] |Molecular Chaperones/metabolism[MESH] |Muscle Proteins/metabolism[MESH] |NF-kappa B/metabolism[MESH] |Neoplasms/drug therapy/*physiopathology[MESH] |Neurodegenerative Diseases/drug therapy/*physiopathology[MESH] |Proteasome Endopeptidase Complex/drug effects/*metabolism[MESH] |Proteasome Inhibitors/*pharmacology/therapeutic use[MESH] |Proteostasis/physiology[MESH] |Tumor Suppressor Protein p53/metabolism[MESH]The proteasome as a druggable target with multiple therapeutic potenti(epmc).pdf DeepDyve Pubget Overpricing